Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

淀粉样变性 医学 仙女座 内科学 人口 淀粉样变性 达拉图穆马 心脏淀粉样变性 硼替佐米 胃肠病学 多发性骨髓瘤 免疫学 免疫球蛋白轻链 环境卫生 物理 银河系 抗体 银河系 量子力学
作者
Michael Rosenzweig,Yvonne A. Efebera,Efstathios Kastritis,Brandon Blue,Faizi Jamal,Monique C. Minnema,Christopher D. Pericone,Sandra Y. Vasey,Yuping Chen,Sonja Kotoulek,Bart Vandael,Joana Duran,Samer K. Khaled,NamPhuong Tran,Jessica Vermeulen,Vaishali Sanchorawala
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4785-4785
标识
DOI:10.1182/blood-2023-181953
摘要

Background: AL amyloidosis is a rare disorder in which deposition of insoluble amyloid fibrils composed of misfolded light chains in vital organs, such as the heart or kidney, leads to serious and life-threatening organ dysfunction. Cardiac involvement is the primary determinant of clinical outcomes for patients with AL amyloidosis, and survival expectations decrease with increasing cardiac stage. Subcutaneous DARA (DARA SC) in combination with VCd recently became the first and only approved treatment for newly diagnosed AL amyloidosis based on results of the phase 3 ANDROMEDA study. In the ANDROMEDA study, a higher hematologic complete response rate was consistently achieved with D-VCd versus VCd in patients with newly diagnosed AL amyloidosis, regardless of baseline cardiac stage (Kastritis E, et al. N Engl J Med. 2021;385[1]:46-58). However, cardiac involvement leads to challenges in the attribution of cardiac events to underlying disease and/or treatments. Additionally, among patients randomized to receive D-VCd in the ANDROMEDA study, 15.4% were Asian, 4.6% were Hispanic or Latino, and 3.1% were Black or African American, limiting the interpretation of safety, efficacy, and pharmacokinetic results among patients of different racial and ethnic backgrounds. Therefore, the ongoing phase 2 AQUARIUS (AMY2009) study will characterize the cardiac safety of different D-VCd treatment regimens in patients with newly diagnosed AL amyloidosis with cardiac involvement to identify potential mitigation strategies for cardiac toxicity, as well as better characterize the safety, efficacy, and pharmacokinetics of D-VCd among racial and ethnic minorities. Study Design and Methods: This ongoing multicenter, multicohort, open-label phase 2 study will enroll ~150 patients aged ≥18 years with newly diagnosed systemic AL amyloidosis and measurable disease from ~45 sites across 10 countries. Patients in Cohort 1 (n = ~120) will have cardiac involvement (AL amyloidosis Mayo Cardiac Stage II and Stage IIIa) with or without other organ involvement. Patients in Cohort 2 (n = ~30) will be of racial or ethnic minority (including ≥15 Black or African American patients) and have ≥1 organ affected by systemic AL amyloidosis. Patients in Cohort 1 will be stratified by baseline cardiac stage (Stages II and IIIa) and randomly assigned (2:1) to receive DARA SC plus immediate VCd (Arm A) or DARA SC plus deferred VCd (Arm B; Figure 1). In both arms, DARA SC (DARA 1,800 mg co-formulated with recombinant human hyaluronidase PH20 [rHuPH20; 2,000 U/mL; ENHANZE ® drug delivery technology, Halozyme, Inc., San Diego, CA, USA]) will be administered QW during Cycles 1-2, Q2W during Cycles 3-6, and Q4W thereafter until a maximum of 24 cycles or the start of subsequent therapy. In Arm A, starting at Cycle 1 Day 1, VCd will be administered weekly in every 28-day cycle for a maximum of 6 cycles. In Arm B, starting at Cycle 4 Day 1, VCd will be administered weekly in every 28-day cycle for a maximum of 6 cycles. Patients in Cohort 2 will receive DARA SC plus immediate VCd. Several unique initiatives were incorporated into the study to enhance enrollment of patients of racial or ethnic minority in Cohort 2, including selecting sites from the ANDROMEDA study that enrolled racially/ethnically diverse patients, targeting new sites in diverse communities, raising awareness of AL amyloidosis and the AQUARIUS study among minority patients at the local and national levels, and educating sites on engagement of patients from diverse backgrounds. The first primary endpoint is incidence of any toxicity grade cardiac events for the different D-VCd treatment regimens (DARA SC + immediate VCd and DARA SC + deferred VCd). The second primary endpoint is trough serum concentration (C trough) of DARA at the end of QW dosing (Cycle 3 Day 1 predose). Efficacy evaluations include assessment of hematologic response and organ response. Data will be summarized using descriptive statistics. The first patient was enrolled on March 17, 2022. As of July 10, 2023, the study has enrolled 75 patients; 71 in Cohort 1 and 4 in Cohort 2. In the US, 2 of the 8 patients enrolled were of racial minority ( Figure 2). Efforts to increase enrollment of minorities continue to be optimized and new collaborative initiatives explored to ensure representative and diverse enrollment in clinical trials. The ClinicalTrials.gov Identifier is NCT05250973.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我是谁的应助被美满的灵安采纳,获得30
1秒前
bml发布了新的文献求助10
1秒前
陈爽er发布了新的文献求助10
2秒前
大模型的应助被聪明笨蛋采纳,获得10
2秒前
ZzAn完成签到,获得积分10
3秒前
3秒前
3秒前
4秒前
4秒前
阔达的鞋子完成签到,获得积分10
5秒前
6qq完成签到,获得积分10
5秒前
小蘑菇的应助被ll采纳,获得10
6秒前
杰瑞发布了新的文献求助10
6秒前
关心发布了新的文献求助10
7秒前
7秒前
8秒前
8秒前
CipherSage的应助被平常的毛衣采纳,获得10
8秒前
迪宝有好运完成签到,获得积分20
9秒前
小C发布了新的文献求助30
10秒前
Jasper的应助被铁子采纳,获得10
10秒前
愤怒野猪发布了新的文献求助10
10秒前
秋风的应助被DW采纳,获得10
10秒前
柠檬小麦青汁完成签到,获得积分10
13秒前
13秒前
wg发布了新的文献求助10
13秒前
jing发布了新的文献求助10
14秒前
陈爽er完成签到,获得积分10
14秒前
春日野荧完成签到,获得积分10
14秒前
yy发布了新的文献求助10
15秒前
哈哈完成签到,获得积分10
15秒前
漾漾完成签到,获得积分10
15秒前
16秒前
17秒前
希望天下0贩的0的应助被不羡采纳,获得10
17秒前
Akim的应助被bml采纳,获得10
17秒前
17秒前
水煮电吹风的应助被meng采纳,获得10
17秒前
花想云完成签到 ,获得积分10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188295
求助须知:如何正确求助?哪些是违规求助? 9576112
关于积分的说明 21845392
捐赠科研通 7786320
什么是DOI,文献DOI怎么找? 3435276
关于科研通互助平台的介绍 2559581
邀请新用户注册赠送积分活动 2482182